Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ISR's Cash to Debt is ranked higher than
93% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.82 vs. ISR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ISR' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: N/A Max: No Debt
Current: No Debt
Equity to Asset 0.89
ISR's Equity to Asset is ranked higher than
90% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ISR: 0.89 )
Ranked among companies with meaningful Equity to Asset only.
ISR' s Equity to Asset Range Over the Past 10 Years
Min: -1.18  Med: 0.83 Max: 0.92
Current: 0.89
-1.18
0.92
Interest Coverage No Debt
ISR's Interest Coverage is ranked higher than
93% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.78 vs. ISR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ISR' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: 6.51
M-Score: -4.09
WACC vs ROIC
6.31%
-40.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -98.84
ISR's Operating margin (%) is ranked lower than
86% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.82 vs. ISR: -98.84 )
Ranked among companies with meaningful Operating margin (%) only.
ISR' s Operating margin (%) Range Over the Past 10 Years
Min: -360.83  Med: -101.44 Max: -56.56
Current: -98.84
-360.83
-56.56
Net-margin (%) -91.40
ISR's Net-margin (%) is ranked lower than
84% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. ISR: -91.40 )
Ranked among companies with meaningful Net-margin (%) only.
ISR' s Net-margin (%) Range Over the Past 10 Years
Min: -412.14  Med: -99.48 Max: -54.25
Current: -91.4
-412.14
-54.25
ROE (%) -23.25
ISR's ROE (%) is ranked lower than
74% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.89 vs. ISR: -23.25 )
Ranked among companies with meaningful ROE (%) only.
ISR' s ROE (%) Range Over the Past 10 Years
Min: -659.02  Med: -49 Max: -16.5
Current: -23.25
-659.02
-16.5
ROA (%) -20.92
ISR's ROA (%) is ranked lower than
75% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. ISR: -20.92 )
Ranked among companies with meaningful ROA (%) only.
ISR' s ROA (%) Range Over the Past 10 Years
Min: -290.54  Med: -41.34 Max: -14.86
Current: -20.92
-290.54
-14.86
ROC (Joel Greenblatt) (%) -75.43
ISR's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.45 vs. ISR: -75.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ISR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -917.05  Med: -94.56 Max: -33.47
Current: -75.43
-917.05
-33.47
Revenue Growth (3Y)(%) -22.00
ISR's Revenue Growth (3Y)(%) is ranked lower than
89% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ISR: -22.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ISR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100 Max: 12.7
Current: -22
0
12.7
EBITDA Growth (3Y)(%) -14.10
ISR's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.90 vs. ISR: -14.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ISR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -79  Med: -22.2 Max: 338
Current: -14.1
-79
338
EPS Growth (3Y)(%) -18.10
ISR's EPS Growth (3Y)(%) is ranked lower than
76% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. ISR: -18.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ISR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.8  Med: -26.7 Max: 233.8
Current: -18.1
-67.8
233.8
» ISR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-09-15)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ISR Guru Trades in Q3 2015

Jeff Auxier 14,218 sh (unchged)
» More
Q4 2015

ISR Guru Trades in Q4 2015

Jeff Auxier 14,218 sh (unchged)
» More
Q1 2016

ISR Guru Trades in Q1 2016

Jeff Auxier 14,218 sh (unchged)
» More
Q2 2016

ISR Guru Trades in Q2 2016

Jeff Auxier 14,218 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ISR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:CASM, OTCPK:TSNLF, NAS:UNIS, NAS:ATEC, AMEX:DXR, OTCPK:PSDLF, NAS:BMRA, NAS:BLFS, NAS:LENS, NAS:PDEX, AMEX:INFU, OTCBB:NEPH, NAS:DXTR, NAS:PLSE, NAS:AKER, NAS:EKSO, OTCPK:IGAP, OTCPK:REPR, OTCPK:STXS, AMEX:MLSS » details
Traded in other countries:AAJ.Germany,
IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes. The Company treats Brain cancer, Head & Neck cancer, Lung cancer, Colon cancer, Ocular cancer, Gynecologic cancer and Prostate cancer using Cesium-131.

IsoRay Inc was organized under Minnesota law in 1983. The Company develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. In 2003, the Company obtained clearance from the FDA for treatment for all solid tumor applications using Cesium-131. Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer; and pancreatic cancer. The brachytherapy seed form of Cesium-131 may be used in surface, interstitial and intracavity applications for tumors with known radio sensitivity. In March 2011, the Company received clearance to commercially deliver Proxcelan Cesium-131 brachytherapy seeds that are preloaded into bioabsorbable braided strands into Europe. Its products include Proxcelan Cesium-131, GliaSite RTS is the only FDA cleared balloon catheter device used in the treatment of brain cancer. The GliaSite RTS and the Company's brachytherapy products used in non-prostate applications typically compete with external beam radiation therapy (EBRT), which can be provided as conventional or intensity modulated radiation therapy, or as stereotactic radiosurgery, a technique that delivers high doses of radiation to a target in a much lower number of sessions than other forms of EBRT. The Company's present and future activities in the development, manufacture and sale of cancer therapy products are subject to extensive laws, regulations, regulatory approvals and guidelines.

Ratios

vs
industry
vs
history
P/B 2.35
ISR's P/B is ranked higher than
62% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. ISR: 2.35 )
Ranked among companies with meaningful P/B only.
ISR' s P/B Range Over the Past 10 Years
Min: 0.31  Med: 3.69 Max: 76.24
Current: 2.35
0.31
76.24
P/S 8.24
ISR's P/S is ranked lower than
83% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.97 vs. ISR: 8.24 )
Ranked among companies with meaningful P/S only.
ISR' s P/S Range Over the Past 10 Years
Min: 0.58  Med: 5.75 Max: 237.5
Current: 8.24
0.58
237.5
Current Ratio 10.92
ISR's Current Ratio is ranked higher than
96% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. ISR: 10.92 )
Ranked among companies with meaningful Current Ratio only.
ISR' s Current Ratio Range Over the Past 10 Years
Min: 0.82  Med: 6.89 Max: 24.59
Current: 10.92
0.82
24.59
Quick Ratio 10.55
ISR's Quick Ratio is ranked higher than
97% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. ISR: 10.55 )
Ranked among companies with meaningful Quick Ratio only.
ISR' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 6.02 Max: 24.21
Current: 10.55
0.68
24.21
Days Inventory 35.87
ISR's Days Inventory is ranked higher than
92% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.07 vs. ISR: 35.87 )
Ranked among companies with meaningful Days Inventory only.
ISR' s Days Inventory Range Over the Past 10 Years
Min: 7.7  Med: 39.96 Max: 64.02
Current: 35.87
7.7
64.02
Days Sales Outstanding 64.66
ISR's Days Sales Outstanding is ranked lower than
57% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 60.82 vs. ISR: 64.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.32  Med: 65.9 Max: 109.1
Current: 64.66
50.32
109.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -21.10
ISR's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.80 vs. ISR: -21.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ISR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -258.5  Med: -14.5 Max: 0
Current: -21.1
-258.5
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.50
ISR's Price/Net Cash is ranked higher than
56% of the 50 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.60 vs. ISR: 12.50 )
Ranked among companies with meaningful Price/Net Cash only.
ISR' s Price/Net Cash Range Over the Past 10 Years
Min: 1  Med: 9.2 Max: 157.5
Current: 12.5
1
157.5
Price/Net Current Asset Value 3.75
ISR's Price/Net Current Asset Value is ranked higher than
76% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.20 vs. ISR: 3.75 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ISR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.71  Med: 6 Max: 175
Current: 3.75
0.71
175
Price/Tangible Book 2.35
ISR's Price/Tangible Book is ranked higher than
69% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.67 vs. ISR: 2.35 )
Ranked among companies with meaningful Price/Tangible Book only.
ISR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.35  Med: 3.81 Max: 71.78
Current: 2.35
0.35
71.78
Price/Median PS Value 1.44
ISR's Price/Median PS Value is ranked lower than
67% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. ISR: 1.44 )
Ranked among companies with meaningful Price/Median PS Value only.
ISR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 1 Max: 36.43
Current: 1.44
0.11
36.43
Earnings Yield (Greenblatt) (%) -12.80
ISR's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. ISR: -12.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ISR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -12.8  Med: 317.8 Max: 16057.5
Current: -12.8
-12.8
16057.5

More Statistics

Revenue (TTM) (Mil) $4.99
EPS (TTM) $ -0.08
Beta0.63
Short Percentage of Float5.00%
52-Week Range $0.55 - 1.65
Shares Outstanding (Mil)55.01

Analyst Estimate

Jun16 Jun17 Jun18 Jun19
Revenue (Mil $) 5 7 10 15
EPS ($) -0.08 -0.02 0.01 0.07
EPS w/o NRI ($) -0.08 -0.02 0.01 0.07
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for AMEX:ISR

Headlines

Articles On GuruFocus.com
IsoRay Inc. Reports Operating Results (10-K) Sep 28 2010 
IsoRay Inc. Reports Operating Results (10-Q) May 12 2010 
IsoRay Inc. Reports Operating Results (10-Q) Nov 12 2009 
IsoRay Inc. Reports Operating Results (10-Q/A) Sep 02 2009 
IsoRay Inc. Reports Operating Results (10-Q) Aug 14 2009 

More From Other Websites
IsoRay, Inc. to Present at Rodman & Renshaw 18th Annual Global Investment Conference Aug 16 2016
ETF’s with exposure to IsoRay, Inc. : August 11, 2016 Aug 11 2016
ISORAY, INC. Files SEC form 8-K, Other Events Jul 08 2016
Women’s Cancer and Cesium-131 Treatments Jul 08 2016
IsoRay® Announces Results of Prospective Trial Presented at Society of Neuro-Oncology Conference Jul 08 2016
Women's Cancer and Cesium-131 Treatments: Topic of Two Presentations at the 2016 Annual Meeting of... Jul 06 2016
ISORAY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jun 24 2016
IsoRay® Announces Results of Prospective Trial Presented at Society of Neuro-Oncology Conference Jun 21 2016
ISRA VISION AG :ISR-DE: Earnings Analysis: Q2, 2016 By the Numbers : June 16, 2016 Jun 16 2016
Court Issues Ruling on IsoRay Motion to Dismiss Securities Lawsuit Jun 14 2016
ISORAY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 13 2016
Court Issues Ruling on IsoRay Motion to Dismiss Securities Lawsuit Jun 02 2016
ISORAY, INC. Financials May 19 2016
IsoRay, Inc. :ISR-US: Earnings Analysis: Q3, 2016 By the Numbers May 17 2016
IsoRay Provides Update on Motion to Dismiss Securities Lawsuit May 16 2016
IsoRay Reports Third Quarter Fiscal 2016 Financial Results May 10 2016
ISORAY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 10 2016
ISORAY, INC. Files SEC form 10-Q, Quarterly Report May 10 2016
IsoRay Announces Third Quarter Fiscal 2016 Financial Results and Early Conclusions from Ongoing... May 10 2016
ISORAY, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement Apr 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)